Utime Ltd Stock Price, News & Analysis

UTime Limited (NASDAQ: UTME) has announced significant changes to its Board of Directors and confirmed its corporate governance stability. The company disclosed the resignation of four directors on September 4, 2025, followed by the appointment of five new directors on September 8-9, 2025.

Key appointments include Wang Tianlong as CEO and Chairman of the Board, along with three independent directors: Ouyang Xuan (Audit Committee Chair), Tong Shirong (Compensation Committee Chair), and Liu Zhongping (Nomination and Governance Committee Chair). Wu Xiaoxia was also appointed as Director.

The company emphasizes that its governance mechanisms remain intact, business operations continue normally, and it maintains commitment to NASDAQ compliance and transparency.

UTime Limited (NASDAQ: WTO), a Chinese mobile device manufacturer and technology company, has announced the change of its official website to http://wtoworld.com effective September 9, 2025.

The company also issued a statement addressing an unauthorized SEC filing regarding its management and board composition. UTime focuses on designing, developing, producing, and selling mobile devices in China and international markets, with an emphasis on cost-effective products for a broad customer base.

UTime Limited (NASDAQ: UTME), a Chinese mobile device manufacturer, has issued an urgent statement addressing an unauthorized SEC filing that falsely claimed changes in company leadership. The company confirms that CEO and Chairman Hengcong Qiu and Director Minfei Bao remain in their positions, contrary to the fraudulent Form 6-K submission.

The company believes the unauthorized filing was made by a former employee with illicit access to EDGAR filing codes. UTime is taking immediate action by notifying the SEC and proper authorities to investigate the matter. The current Board of Directors, consisting of Minfei Bao, Hengcong Qiu, Xiaoqian Jia, Hailin Xie, and Yanzhi Wang, remains unchanged.

UTime Limited (NASDAQ: UTME) has received a notification from Nasdaq on August 15, 2025, indicating non-compliance with the minimum stockholders' equity requirement. The company's stockholders' equity has fallen below the required $2.5 million threshold for continued listing on the Nasdaq Capital Market.

The company has been given 45 calendar days until September 29, 2025, to submit a compliance plan. If accepted by Nasdaq, UTime could receive up to 180 calendar days extension to regain compliance. The notification does not immediately affect UTME's listing status on Nasdaq.

UTime (Nasdaq: WTO) has announced a 1-for-10 reverse share split of its Class A ordinary shares, effective March 31, 2025. The move aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.

Key details of the reverse split include:

• Outstanding shares will reduce from approximately 36 million to 3.6 million
• New par value will be $0.001 per share
• Trading continues under symbol 'WTO' with new CUSIP number G9411M124
• Fractional shares will be rounded up to the nearest whole number

The split will also affect ordinary shares issuable under outstanding derivative securities and equity incentive plans. VStock Transfer, will serve as the exchange agent, with shareholders holding book-entry or brokerage accounts requiring no action.

UTime (Nasdaq: WTO) announced receiving a notification letter from Nasdaq on October 10, 2024, regarding its failure to meet the minimum bid price requirement. The company's ordinary shares have been below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). UTime has until April 8, 2025, to regain compliance by maintaining a closing bid price of at least $1 for a minimum of 10 consecutive business days.

If UTime fails to meet this requirement within the initial 180-day period, it may be eligible for an additional 180 calendar days, provided it meets other continued listing requirements and submits a written notice of intention to cure the deficiency. The notification has no immediate effect on UTime's Nasdaq listing.

UTime (Nasdaq: WTO), a mobile device manufacturer, has announced a $5 million registered direct offering of its ordinary shares. The company has agreed to sell 7,692,308 ordinary shares at a purchase price of $0.65 per share to certain accredited investors. The offering is expected to close around September 16, 2024, subject to customary closing conditions. The shares are being offered pursuant to a shelf registration statement on Form F-3 filed with the SEC. UTime aims to provide cost-effective products and solutions to consumers globally, particularly focusing on low-income individuals in established and emerging markets.

UTime (Nasdaq: WTO) has announced a 1-for-25 reverse share split, effective September 11, 2024. This move aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per ordinary share. Key points include:

• Trading on a split-adjusted basis begins September 11, 2024
• New CUSIP number: G9411M116
• Outstanding shares will reduce from ~450 million to ~18 million
• No fractional shares will be issued; all fractional interests rounded up
• Adjustments will be made to outstanding derivative securities and equity incentive plans

VStock Transfer, is acting as the exchange agent. Shareholders with book-entry or brokerage accounts need not take action, while those with certificates will receive instructions for the exchange process.

UTime (NASDAQ: WTO) has initiated comprehensive financial and legal due diligence on Bowen Therapeutics Inc, marking a significant step in its planned acquisition. This move aligns with UTime's strategy to expand its presence in the innovative medical products sector and strengthen its market position. Bowen Therapeutics, known for its research and development capabilities, particularly in monkeypox vaccine development, is expected to become a key part of UTime's expansion strategy.

The due diligence process will cover various aspects of Bowen Therapeutics' business, including financial statements, assets, liabilities, cash flow, tax records, corporate governance, contracts, intellectual property rights, and potential legal risks. This thorough examination will provide UTime with a comprehensive understanding of Bowen Therapeutics, enabling informed decision-making aligned with its long-term growth strategy in the global healthcare sector.